Immunotherapy: Vaccine trials in melanoma -- time for reflection

Nat Rev Clin Oncol. 2009 May;6(5):256-8. doi: 10.1038/nrclinonc.2009.42.

Abstract

The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.

Publication types

  • Comment

MeSH terms

  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / immunology
  • Dose-Response Relationship, Drug
  • Humans
  • Immunotherapy*
  • Interleukin-2 / therapeutic use
  • Melanoma / pathology*
  • Melanoma / secondary
  • Melanoma / therapy*
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Randomized Controlled Trials as Topic
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy*

Substances

  • Cancer Vaccines
  • Interleukin-2